Association Between a 22-feature Genomic Classifier and Biopsy Gleason Upgrade During Active Surveillance for Prostate Cancer
Authors:
Open Access
- 11 February 2022
- journal article
- research article
- Published by Elsevier in European Urology Open Science
- Vol. 37, 113-119
Abstract
No abstract availableKeywords
All Related Versions
This publication has 28 references indexed in Scilit:
- Validation of the Decipher Test for predicting adverse pathology in candidates for prostate cancer active surveillanceProstate Cancer and Prostatic Diseases, 2018
- Quantified Clinical Risk Change as an End Point During Prostate Cancer Active SurveillanceEuropean Urology, 2017
- Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer: The PRECISE Recommendations—A Report of a European School of Oncology Task ForceEuropean Urology, 2017
- Long-term Results of Active Surveillance in the Göteborg Randomized, Population-based Prostate Cancer Screening TrialEuropean Urology, 2016
- 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate CancerNew England Journal of Medicine, 2016
- Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline EndorsementJournal of Clinical Oncology, 2016
- Trends in Management for Patients With Localized Prostate Cancer, 1990-2013JAMA, 2015
- Contemporary Use of Initial Active Surveillance Among Men in Michigan with Low-risk Prostate CancerEuropean Urology, 2015
- Modeling grade progression in an active surveillance studyStatistics in Medicine, 2013
- Clinical Results of Long-Term Follow-Up of a Large, Active Surveillance Cohort With Localized Prostate CancerJournal of Clinical Oncology, 2010